+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Companion Diagnostics Market by Product & Service (Assay, Kit, Software & Service), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Lung & Gastric Cancer, Neurological Disease), End-User (Pharma Companies, CRO), Region - Global Forecast to 2025

  • ID: 5129617
  • Report
  • July 2020
  • Region: Global
  • 320 Pages
  • Markets and Markets
1 of 6
The Companion Diagnostics Market is Expected to reach USD 6.8 Billion by 2025 from USD 3.7 Billion in 2020, at a CAGR of 12.9%.

FEATURED COMPANIES

  • Abbott Laboratories, Inc.
  • Amoy Diagnostics Co. Ltd.
  • Danaher Corporation
  • Icon plc
  • Myriad Genetics, Inc.
  • Q² Solutions
  • MORE

The companion diagnostics market is estimated to grow at a CAGR of 12.9%

The growth of the companion diagnostics industry is tied primarily to its various advantages, the growing need for targeted therapy, the increasing importance of personalized medicine. Moreover, the increasing global incidence of cancer, ever-increasing application areas of companion diagnostics, rising demand for next-generation sequencing, the growing significance of companion diagnostics in drug development, and the increasing number of clinical trials are expected to present growth opportunities for players in the market. However, the high cost of companion diagnostic tests and the uncertain reimbursement scenario in different regions affect market growth to a certain extent during the forecast period.

Cancer segment to witness the highest growth during the forecast period

The cancer segment is estimated to grow at the highest CAGR during the forecast period. This can be attributed primarily to the increasing global incidence of cancer, the growing role of companion diagnostics in personalized medicine treatment for cancer, the rising utility of biomarkers in the diagnosis of cancer, technological advancements in cancer diagnostics at the molecular level, and the availability of funding for cancer research.

Pharmaceutical & biopharmaceutical companies segment to grow at the highest CAGR in the companion diagnostics market, by end-user

The major factors driving the demand for pharmaceutical & biopharmaceutical companies in companion diagnostics are growing prominence in drug development and the growing importance of companion diagnostic biomarkers. The increasing demand for personalized medicine as well as the high demand for targeted therapies for various diseases and disorders are also expected to drive the demand and uptake of companion diagnostics among pharmaceutical & biopharmaceutical companies.

APAC market to witness the highest growth during the forecast period

The Asia Pacific is estimated to be the fastest-growing regional market for companion diagnostics during the forecast period. The high incidence of cancer, growing proteomics & genomics research, increasing research funding, rising investments by pharmaceutical and biotechnology companies, and growing awareness about personalized therapeutics in several APAC countries are some of the major factors driving the growth of this market.

The break-down of primary participants is as mentioned below:

  • By Company Type - Tier 1: 40%, Tier 2: 25%, and Tier 3: 35%
  • By Designation - C-level: 33%, Director-level: 41%, and Others: 26%
  • By Region - North America: 38%, Europe: 32%, Asia Pacific: 23%, Latin America: 5%, and the Middle East & Africa: 2%

The prominent players operating in the global companion diagnostics market are F. Hoffmann-La Roche AG (Switzerland), Agilent Technologies, Inc. (US), QIAGEN N.V. (Germany), Abbott Laboratories, Inc. (US), Almac Group (UK), Danaher Corporation (US), Illumina, Inc. (US), bioMérieux SA (France), Myriad Genetics, Inc., (US), Sysmex Corporation (Japan), Thermo Fisher Scientific Inc. (US), Abnova Corporation (Taiwan), Guardant Health, Inc. (US), Icon Plc (Ireland), and Biogenex Laboratories, Inc. (US)

Research Coverage:
This report analyzes the market for various companion diagnostics and their adoption patterns. It aims at estimating the size and future growth potential of the global companion diagnostics market as well as its segments (by product & service, technology, indication, end-user, and region). The report also includes an in-depth competitive analysis of key market players along with their company profiles, product offerings, and recent developments.

Reasons to Buy the Report

This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one, or any combination of the below mentioned five strategies for strengthening their market presence.

  • Market Penetration: Comprehensive information on the product portfolios offered by the top players in the global companion diagnostics market
  • Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and service launches in the global companion diagnostics market
  • Market Development: Comprehensive information on the lucrative emerging regions
  • Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the global companion diagnostics market
  • Competitive Assessment: In-depth assessment of product offered, market shares, growth strategies, and revenue analysis of leading players in the global companion diagnostics market
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Abbott Laboratories, Inc.
  • Amoy Diagnostics Co. Ltd.
  • Danaher Corporation
  • Icon plc
  • Myriad Genetics, Inc.
  • Q² Solutions
  • MORE

1 Introduction
1.1 Objectives of the Study
1.2 Market Definition
1.2.1 Inclusions & Exclusions
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
Table 1 Standard Currency Conversion Rates
1.5 Limitations
1.6 Stakeholders
1.7 Summary of Changes

2 Research Methodology
2.1 Research Data
Figure 1 Research Design
2.1.1 Secondary Data
2.1.1.1 Key Data from Secondary Sources
2.1.2 Primary Data
Figure 2 Primary Sources
2.1.2.1 Key Data from Primary Sources
2.1.2.2 Key Industry Insights
Figure 3 Breakdown of Primary Interviews: by Company Type, Designation, and Region
2.2 Market Size Estimation
Figure 4 Market Size Estimation: Revenue Share Analysis
Figure 5 Revenue Share Analysis Illustration
Figure 6 Market Size Approach
Figure 7 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
Figure 8 Data Triangulation Methodology
2.4 Market Share Analysis
2.5 Assumptions for the Study

3 Executive Summary
Figure 9 Companion Diagnostics Market, by Product & Service, 2020 Vs. 2025 (USD Billion)
Figure 10 Companion Diagnostics Market, by Technology, 2020 Vs. 2025 (USD Billion)
Figure 11 Companion Diagnostics Market, by Indication, 2020 Vs. 2025 (USD Billion)
Figure 12 Companion Diagnostics Market, by End-user, 2020 Vs. 2025 (USD Billion)
Figure 13 Geographical Snapshot of the Companion Diagnostics Market

4 Premium Insights
4.1 Companion Diagnostics Market Overview
Figure 14 Increasing Demand for Targeted Therapies and Personalized Medicine in the Pharmaceutical Industry to Drive Market Growth
4.2 Asia-Pacific: Companion Diagnostics Market, by End-user (2019)
Figure 15 Pharmaceutical & Biopharmaceutical Companies Commanded the Largest Share of the APAC Companion Diagnostics Market in 2019
4.3 Regional Mix: Companion Diagnostics Market
Figure 16 Asia-Pacific to Witness the Highest Growth in the Forecast Period
4.4 Companion Diagnostics Market: Developed Vs. Developing Countries
Figure 17 Developing Countries to Register Higher Growth During the Forecast Period
4.5 Geographical Snapshot of the Companion Diagnostics Market
Figure 18 China to Grow at the Highest CAGR During the Forecast Period

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
Figure 19 Companion Diagnostics Market: Drivers, Restraints, Opportunities, and Challenges
5.2.1 Drivers
5.2.1.1 Advantages of Companion Diagnostics
5.2.1.2 Growing Need for Targeted Therapy
5.2.1.3 Growing Importance of Personalized Medicine
Figure 20 Global Launch of Personalized Medicine Products, 2008-2016
5.2.1.4 Increasing Global Incidence of Cancer
Figure 21 Global Cancer Incidence, 2008-2030
5.2.1.5 Growing Application Areas of Companion Diagnostics
5.2.2 Restraints
5.2.2.1 High Cost of Companion Diagnostic Tests
5.2.2.2 Uncertain Reimbursement Scenario in Different Regions
Table 2 Companion Diagnostics Reimbursement Scenario Worldwide
5.2.3 Opportunities
5.2.3.1 Increasing Demand for Next-Generation Sequencing
Table 3 Partnerships & Collaborations for Developing Ngs-Based Companion Diagnostic Tests
5.2.3.2 Growing Significance of Companion Diagnostics in Drug Development
5.2.3.3 Increasing Number of Clinical Trials
Table 4 List of Clinical Trials for Companion Diagnostics
5.2.4 Challenges
5.2.4.1 Impact of the COVID-19 Pandemic
5.2.4.2 Shortage of Trained Professionals

6 Industry Insights
6.1 Introduction
6.2 Industry Trends
6.2.1 Impact of the COVID-19 Pandemic on the Companion Diagnostics Market
Figure 22 Impact of COVID-19 on the Companion Diagnostics Market
6.2.2 Growing Focus on Liquid Biopsy in Companion Diagnostics
6.2.3 Increasing Collaborations
Table 5 Recent Collaborations in the Companion Diagnostics Market
6.3 Regulatory Analysis
6.3.1 North America
6.3.1.1 US
Table 6 US: Classification of Medical Devices
Figure 23 Premarket Notification: 510(K) Approval for Companion Diagnostic Products
6.3.1.2 Canada
6.3.2 Europe
6.3.3 Asia-Pacific
6.3.3.1 Australia
6.3.3.2 Japan
Table 7 Japan: Classification of Medical Devices
6.3.3.3 China
Table 8 China: Time, Cost, and Complexity of Registration Process
6.3.3.4 India
Figure 24 India: Regulatory Process for IVD Devices
Table 9 India: Time, Cost, and Complexity of Registration Process
6.3.4 Brazil
6.4 Product Pipeline Analysis
Table 10 Companion Diagnostics Product Pipeline Analysis, by Market Player: Current Market Scenario

7 Companion Diagnostics Market, by Product & Service
7.1 Introduction
Table 11 Companion Diagnostics Market, by Product & Service, 2017-2019 (USD Million)
Table 12 Companion Diagnostics Market, by Product & Service, 2020-2025 (USD Million)
7.2 Impact of COVID-19 on the Demand and Supply of Companion Diagnostic Products & Services
7.3 Assays, Kits, and Reagents
7.3.1 Increasing Volume of Cdx Tests Performed in Laboratories to Support the Adoption of Assays & Kits
Table 13 Companion Diagnostic Assays, Kits, and Reagents Market, by Country, 2017-2019 (USD Million)
Table 14 Companion Diagnostic Assays, Kits, and Reagents Market, by Country, 2020-2025 (USD Million)
7.4 Software & Services
7.4.1 Need for Effective Data Management Software Within Laboratories to Contribute to Market Growth
Table 15 Companion Diagnostic Software & Services Market, by Country, 2017-2019 (USD Million)
Table 16 Companion Diagnostic Software & Services Market, by Country, 2020-2025 (USD Million)

8 Companion Diagnostics Market, by Technology
8.1 Introduction
Table 17 Companion Diagnostics Market, by Technology, 2017-2019 (USD Million)
Table 18 Companion Diagnostics Market, by Technology, 2020-2025 (USD Million)
8.2 Impact of COVID-19 on the Companion Diagnostic Technology Market
8.3 Polymerase Chain Reaction (Pcr)
8.3.1 Growing Applications of Pcr Technologies in Personalized Medicine and Companion Diagnostics to Drive Growth
Table 19 Comparison of Tissue Sequencing Platforms for the Detection of Ras/Braf Mutation
Table 20 Major Pcr Tests/Kits Available in the Market
Table 21 Companion Diagnostics Market for Polymerase Chain Reaction, by Country, 2017-2019 (USD Million)
Table 22 Companion Diagnostics Market for Polymerase Chain Reaction, by Country, 2020-2025 (USD Million)
8.4 Next-Generation Sequencing (Ngs)
8.4.1 Ngs Segment to Grow at Highest CAGR During Forecast Period
Table 23 Major Ngs Tests/Kits Available in the Market
Table 24 Companion Diagnostics Market for Next-Generation Sequencing, by Country, 2017-2019 (USD Million)
Table 25 Companion Diagnostics Market for Next-Generation Sequencing, by Country, 2020-2025 (USD Million)
8.5 in Situ Hybridization (Ish)
8.5.1 Advancements in Ish and Its Demand in Small-Tumor Diagnostics to Drive Growth
Table 26 Major Ish Tests/Kits Available in the Market
Table 27 Companion Diagnostics Market for in Situ Hybridization, by Country, 2017-2019 (USD Million)
Table 28 Companion Diagnostics Market for in Situ Hybridization, by Country, 2020-2025 (USD Million)
8.6 Immunohistochemistry (Ihc)
8.6.1 Increasing Demand for User-Friendly and Cost-Effective Technologies in Cdx to Support Growth in this Segment
Table 29 Major Ihc Tests/Kits Available in the Market
Table 30 Companion Diagnostics Market for Immunohistochemistry, by Country, 2017-2019 (USD Million)
Table 31 Companion Diagnostics Market for Immunohistochemistry, by Country, 2020-2025 (USD Million)
8.7 Other Technologies
Table 32 Companion Diagnostics Market for Other Technologies, by Country, 2017-2019 (USD Million)
Table 33 Companion Diagnostics Market for Other Technologies, by Country, 2020-2025 (USD Million)

9 Companion Diagnostics Market, by Indication
9.1 Introduction
Table 34 Companion Diagnostics Market, by Indication, 2017-2019 (USD Million)
Table 35 Companion Diagnostics Market, by Indication, 2020-2025 (USD Million)
9.2 Impact of COVID-19 on Various Indications in the Companion Diagnostics Market
9.3 Cancer
Figure 25 Breast Cancer to Dominate the Companion Diagnostics Market for Cancer During the Forecast Period
Table 36 Companion Diagnostics Market for Cancer, by Type, 2017-2019 (USD Million)
Table 37 Companion Diagnostics Market for Cancer, by Type, 2020-2025 (USD Million)
Table 38 Companion Diagnostics Market for Cancer, by Country, 2017-2019 (USD Million)
Table 39 Companion Diagnostics Market for Cancer, by Country, 2020-2025 (USD Million)
9.3.1 Breast Cancer
9.3.1.1 Breast Cancer is the Most Common Cancer Among Women-A Key Factor Contributing to the Large Share of this Market Segment
Table 40 Companion Diagnostics Market for Breast Cancer, by Country, 2017-2019 (USD Million)
Table 41 Companion Diagnostics Market for Breast Cancer, by Country, 2020-2025 (USD Million)
9.3.2 Lung Cancer
9.3.2.1 Growing Demand for Therapeutic Drugs and Their High Efficacy in the Treatment of Lung Cancer to Increase Cdx Adoption
Figure 26 Global Lung Cancer Incidence, 2012-2030
Table 42 Companion Diagnostics Market for Lung Cancer, by Country, 2017-2019 (USD Million)
Table 43 Companion Diagnostics Market for Lung Cancer, by Country, 2020-2025 (USD Million)
9.3.3 Colorectal Cancer
9.3.3.1 Growing Need for Molecular Profiling of Primary Tumors in Colorectal Cancer to Drive Growth in this Market Segment
Table 44 Companion Diagnostics Market for Colorectal Cancer, by Country, 2017-2019 (USD Million)
Table 45 Companion Diagnostics Market for Colorectal Cancer, by Country, 2020-2025 (USD Million)
9.3.4 Melanoma
9.3.4.1 Growing Incidence of Melanoma Drives the Demand for Companion Diagnostics
Table 46 Companion Diagnostics Market for Melanoma, by Country, 2017-2019 (USD Million)
Table 47 Companion Diagnostics Market for Melanoma, by Country, 2020-2025 (USD Million)
9.3.5 Gastric Cancer
9.3.5.1 Increasing Focus of Market Players on the Development of Tests and Kits for Gastric Cancer Indications to Drive Market Growth
Table 48 Companion Diagnostics Market for Gastric Cancer, by Country, 2017-2019 (USD Million)
Table 49 Companion Diagnostics Market for Gastric Cancer, by Country, 2020-2025 (USD Million)
9.4 Infectious Diseases
9.4.1 Growing Focus of Companion Diagnostic Players on Orphan Indications to Propel the Growth of this Segment
Table 50 Companion Diagnostics Market for Infectious Diseases, by Country, 2017-2019 (USD Million)
Table 51 Companion Diagnostics Market for Infectious Diseases, by Country, 2020-2025 (USD Million)
9.5 Cardiovascular Diseases
9.5.1 Growing Demand for Targeted Therapies Due to High Incidence of Cardiovascular Diseases to Drive Growth
Table 52 Companion Diagnostics Market for Cardiovascular Diseases, by Country, 2017-2019 (USD Million)
Table 53 Companion Diagnostics Market for Cardiovascular Diseases, by Country, 2020-2025 (USD Million)
9.6 Neurological Diseases
9.6.1 Growing Number of Diagnostic Technologies for the Treatment of Neurological Diseases to Boost the Adoption of Companion Diagnostics
Table 54 Companion Diagnostics Market for Neurological Diseases, by Country, 2017-2019 (USD Million)
Table 55 Companion Diagnostics Market for Neurological Diseases, by Country, 2020-2025 (USD Million)
9.7 Other Indications
Table 56 Companion Diagnostics Market for Other Indications, by Country, 2017-2019 (USD Million)
Table 57 Companion Diagnostics Market for Other Indications, by Country, 2020-2025 (USD Million)

10 Companion Diagnostics Market, by End-user
10.1 Introduction
Table 58 Companion Diagnostics Market, by End-user, 2017-2019 (USD Million)
Table 59 Companion Diagnostics Market, by End-user, 2020-2025 (USD Million)
10.2 Impact of COVID-19 on the End-users in the Companion Diagnostics Market
10.3 Pharmaceutical & Biopharmaceutical Companies
10.3.1 Wide Usage of Cdx in Pharmaceutical & Biopharmaceutical Companies to Drive Market Growth
Table 60 Companion Diagnostics Market for Pharmaceutical & Biopharmaceutical Companies, by Country, 2017-2019 (USD Million)
Table 61 Companion Diagnostics Market for Pharmaceutical & Biopharmaceutical Companies, by Country, 2020-2025 (USD Million)
10.4 Reference Laboratories
10.4.1 Growing Incidence of and Rising Demand for Targeted Therapies to Drive Growth
Table 62 Companion Diagnostics Market for Reference Laboratories, by Country, 2017-2019 (USD Million)
Table 63 Companion Diagnostics Market for Reference Laboratories, by Country, 2020-2025 (USD Million)
10.5 Contract Research Organizations
10.5.1 Cros Offer a Complete Range of Companion Diagnostic Services to Targeted Therapy-Related Clinical Trials
Table 64 Companion Diagnostics Market for Contract Research Organizations, by Country, 2017-2019 (USD Million)
Table 65 Companion Diagnostics Market for Contract Research Organizations, by Country, 2020-2025 (USD Million)
10.6 Other End-users
Table 66 Companion Diagnostics Market for Other End-users, by Country, 2017-2019 (USD Million)
Table 67 Companion Diagnostics Market for Other End-users, by Country, 2020-2025 (USD Million)

11 Companion Diagnostics Market, by Region
11.1 Introduction
Figure 27 Geographic Snapshot: China is Expected to Grow at the Highest CAGR During the Forecast Period
Table 68 Companion Diagnostics Market, by Region, 2017-2019 (USD Million)
Table 69 Companion Diagnostics Market, by Region, 2020-2025 (USD Million)
11.2 Impact of COVID-19 on Various Regions in the Companion Diagnostics Market
11.3 North America
Figure 28 North America: Companion Diagnostics Market Snapshot
Table 70 North America: Companion Diagnostics Market, by Country, 2017-2019 (USD Million)
Table 71 North America: Companion Diagnostics Market, by Country, 2020-2025 (USD Million)
Table 72 North America: Companion Diagnostics Market, by Product & Service, 2017-2019 (USD Million)
Table 73 North America: Companion Diagnostics Market, by Product & Service, 2020-2025 (USD Million)
Table 74 North America: Companion Diagnostics Market, by Technology, 2017-2019 (USD Million)
Table 75 North America: Companion Diagnostics Market, by Technology, 2020-2025 (USD Million)
Table 76 North America: Companion Diagnostics Market, by Indication, 2017-2019 (USD Million)
Table 77 North America: Companion Diagnostics Market, by Indication, 2020-2025 (USD Million)
Table 78 North America: Companion Diagnostics Market for Cancer, by Type, 2017-2019 (USD Million)
Table 79 North America: Companion Diagnostics Market for Cancer, by Type, 2020-2025 (USD Million)
Table 80 North America: Companion Diagnostics Market, by End-user, 2017-2019 (USD Million)
Table 81 North America: Companion Diagnostics Market, by End-user, 2020-2025 (USD Million)
11.3.1 US
11.3.1.1 US is the Largest Market for Companion Diagnostics in North America
Table 82 US: Key Macroindicators
Table 83 US: Companion Diagnostics Market, by Product & Service, 2017-2019 (USD Million)
Table 84 US: Companion Diagnostics Market, by Product & Service, 2020-2025 (USD Million)
Table 85 US: Companion Diagnostics Market, by Technology, 2017-2019 (USD Million)
Table 86 US: Companion Diagnostics Market, by Technology, 2020-2025 (USD Million)
Table 87 US: Companion Diagnostics Market, by Indication, 2017-2019 (USD Million)
Table 88 US: Companion Diagnostics Market, by Indication, 2020-2025 (USD Million)
Table 89 US: Companion Diagnostics Market for Cancer, by Type, 2017-2019 (USD Million)
Table 90 US: Companion Diagnostics Market for Cancer, by Type, 2020-2025 (USD Million)
Table 91 US: Companion Diagnostics Market, by End-user, 2017-2019 (USD Million)
Table 92 US: Companion Diagnostics Market, by End-user, 2020-2025 (USD Million)
11.3.2 Canada
11.3.2.1 Government Initiatives to Promote Companion Diagnostics in Various Indications to Drive Market Growth in Canada
Table 93 Canada: Key Macroindicators
Table 94 Canada: Companion Diagnostics Market, by Product & Service, 2017-2019 (USD Million)
Table 95 Canada: Companion Diagnostics Market, by Product & Service, 2020-2025 (USD Million)
Table 96 Canada: Companion Diagnostics Market, by Technology, 2017-2019 (USD Million)
Table 97 Canada: Companion Diagnostics Market, by Technology, 2020-2025 (USD Million)
Table 98 Canada: Companion Diagnostics Market, by Indication, 2017-2019 (USD Million)
Table 99 Canada: Companion Diagnostics Market, by Indication, 2020-2025 (USD Million)
Table 100 Canada: Companion Diagnostics Market for Cancer, by Type, 2017-2019 (USD Million)
Table 101 Canada: Companion Diagnostics Market for Cancer, by Type, 2020-2025 (USD Million)
Table 102 Canada: Companion Diagnostics Market, by End-user, 2017-2019 (USD Million)
Table 103 Canada: Companion Diagnostics Market, by End-user, 2020-2025 (USD Million)
11.4 Europe
Table 104 Europe: Companion Diagnostics Market, by Country, 2017-2019 (USD Million)
Table 105 Europe: Companion Diagnostics Market, by Country, 2020-2025 (USD Million)
Table 106 Europe: Companion Diagnostics Market, by Product & Service, 2017-2019 (USD Million)
Table 107 Europe: Companion Diagnostics Market, by Product & Service, 2020-2025 (USD Million)
Table 108 Europe: Companion Diagnostics Market, by Technology, 2017-2019 (USD Million)
Table 109 Europe: Companion Diagnostics Market, by Technology, 2020-2025 (USD Million)
Table 110 Europe: Companion Diagnostics Market, by Indication, 2017-2019 (USD Million)
Table 111 Europe: Companion Diagnostics Market, by Indication, 2020-2025 (USD Million)
Table 112 Europe: Companion Diagnostics Market for Cancer, by Type, 2017-2019 (USD Million)
Table 113 Europe: Companion Diagnostics Market for Cancer, by Type, 2020-2025 (USD Million)
Table 114 Europe: Companion Diagnostics Market, by End-user, 2017-2019 (USD Million)
Table 115 Europe: Companion Diagnostics Market, by End-user, 2020-2025 (USD Million)
11.4.1 Germany
11.4.1.1 Germany is a Major Market for Pharmaceutical and Biotechnology Products in Europe
Table 116 Germany: Key Macroindicators
Table 117 Germany: Companion Diagnostics Market, by Product & Service, 2017-2019 (USD Million)
Table 118 Germany: Companion Diagnostics Market, by Product & Service, 2020-2025 (USD Million)
Table 119 Germany: Companion Diagnostics Market, by Technology, 2017-2019 (USD Million)
Table 120 Germany: Companion Diagnostics Market, by Technology, 2020-2025 (USD Million)
Table 121 Germany: Companion Diagnostics Market, by Indication, 2017-2019 (USD Million)
Table 122 Germany: Companion Diagnostics Market, by Indication, 2020-2025 (USD Million)
Table 123 Germany: Companion Diagnostics Market for Cancer, by Type, 2017-2019 (USD Million)
Table 124 Germany: Companion Diagnostics Market for Cancer, by Type, 2020-2025 (USD Million)
Table 125 Germany: Companion Diagnostics Market, by End-user, 2017-2019 (USD Million)
Table 126 Germany: Companion Diagnostics Market, by End-user, 2020-2025 (USD Million)
11.4.2 UK
11.4.2.1 Growth in the Country’s Life Science Industry and Increasing Research Are Key Factors Driving Market Growth in the UK
Table 127 UK: Key Macroindicators
Table 128 UK: Companion Diagnostics Market, by Product & Service, 2017-2019 (USD Million)
Table 129 UK: Companion Diagnostics Market, by Product & Service, 2020-2025 (USD Million)
Table 130 UK: Companion Diagnostics Market, by Technology, 2017-2019 (USD Million)
Table 131 UK: Companion Diagnostics Market, by Technology, 2020-2025 (USD Million)
Table 132 UK: Companion Diagnostics Market, by Indication, 2017-2019 (USD Million)
Table 133 UK: Companion Diagnostics Market, by Indication, 2020-2025 (USD Million)
Table 134 UK: Companion Diagnostics Market for Cancer, by Type, 2017-2019 (USD Million)
Table 135 UK: Companion Diagnostics Market for Cancer, by Type, 2020-2025 (USD Million)
Table 136 UK: Companion Diagnostics Market, by End-user, 2017-2019 (USD Million)
Table 137 UK: Companion Diagnostics Market, by End-user, 2020-2025 (USD Million)
11.4.3 Switzerland
11.4.3.1 Switzerland Boasts a Strong Research-Oriented Pharma Industry, a Key Factor Supporting Market Growth
Table 138 Switzerland: Key Macroindicators
Table 139 Switzerland: Companion Diagnostics Market, by Product & Service, 2017-2019 (USD Million)
Table 140 Switzerland: Companion Diagnostics Market, by Product & Service, 2020-2025 (USD Million)
Table 141 Switzerland: Companion Diagnostics Market, by Technology, 2017-2019 (USD Million)
Table 142 Switzerland: Companion Diagnostics Market, by Technology, 2020-2025 (USD Million)
Table 143 Switzerland: Companion Diagnostics Market, by Indication, 2017-2019 (USD Million)
Table 144 Switzerland: Companion Diagnostics Market, by Indication, 2020-2025 (USD Million)
Table 145 Switzerland: Companion Diagnostics Market for Cancer, by Type, 2017-2019 (USD Million)
Table 146 Switzerland: Companion Diagnostics Market for Cancer, by Type, 2020-2025 (USD Million)
Table 147 Switzerland: Companion Diagnostics Market, by End-user, 2017-2019 (USD Million)
Table 148 Switzerland: Companion Diagnostics Market, by End-user, 2020-2025 (USD Million)
11.4.4 France
11.4.4.1 Increasing Government Funding for Genomics and Personalized Therapeutics R&D is Driving Market Growth
Table 149 France: Key Macroindicators
Table 150 France: Companion Diagnostics Market, by Product & Service, 2017-2019 (USD Million)
Table 151 France: Companion Diagnostics Market, by Product & Service, 2020-2025 (USD Million)
Table 152 France: Companion Diagnostics Market, by Technology, 2017-2019 (USD Million)
Table 153 France: Companion Diagnostics Market, by Technology, 2020-2025 (USD Million)
Table 154 France: Companion Diagnostics Market, by Indication, 2017-2019 (USD Million)
Table 155 France: Companion Diagnostics Market, by Indication, 2020-2025 (USD Million)
Table 156 France: Companion Diagnostics Market for Cancer, by Type, 2017-2019 (USD Million)
Table 157 France: Companion Diagnostics Market for Cancer, by Type, 2020-2025 (USD Million)
Table 158 France: Companion Diagnostics Market, by End-user, 2017-2019 (USD Million)
Table 159 France: Companion Diagnostics Market, by End-user, 2020-2025 (USD Million)
11.4.5 Italy
11.4.5.1 Growing Disease Prevalence Has Contributed to the Demand for Better, More Powerful Therapeutics in Italy
Table 160 Italy: Key Macroindicators
Table 161 Italy: Companion Diagnostics Market, by Product & Service, 2017-2019 (USD Million)
Table 162 Italy: Companion Diagnostics Market, by Product & Service, 2020-2025 (USD Million)
Table 163 Italy: Companion Diagnostics Market, by Technology, 2017-2019 (USD Million)
Table 164 Italy: Companion Diagnostics Market, by Technology, 2020-2025 (USD Million)
Table 165 Italy: Companion Diagnostics Market, by Indication, 2017-2019 (USD Million)
Table 166 Italy: Companion Diagnostics Market, by Indication, 2020-2025 (USD Million)
Table 167 Italy: Companion Diagnostics Market for Cancer, by Type, 2017-2019 (USD Million)
Table 168 Italy: Companion Diagnostics Market for Cancer, by Type, 2020-2025 (USD Million)
Table 169 Italy: Companion Diagnostics Market, by End-user, 2017-2019 (USD Million)
Table 170 Italy: Companion Diagnostics Market, by End-user, 2020-2025 (USD Million)
11.4.6 Spain
11.4.6.1 Medical Institutes in Spain Are Increasingly Focusing on Cancer Biomarker Research
Table 171 Spain: Key Macroindicators
Table 172 Spain: Companion Diagnostics Market, by Product & Service, 2017-2019 (USD Million)
Table 173 Spain: Companion Diagnostics Market, by Product & Service, 2020-2025 (USD Million)
Table 174 Spain: Companion Diagnostics Market, by Technology, 2017-2019 (USD Million)
Table 175 Spain: Companion Diagnostics Market, by Technology, 2020-2025 (USD Million)
Table 176 Spain: Companion Diagnostics Market, by Indication, 2017-2019 (USD Million)
Table 177 Spain: Companion Diagnostics Market, by Indication, 2020-2025 (USD Million)
Table 178 Spain: Companion Diagnostics Market for Cancer, by Type, 2017-2019 (USD Million)
Table 179 Spain: Companion Diagnostics Market for Cancer, by Type, 2020-2025 (USD Million)
Table 180 Spain: Companion Diagnostics Market, by End-user, 2017-2019 (USD Million)
Table 181 Spain: Companion Diagnostics Market, by End-user, 2020-2025 (USD Million)
11.4.7 Rest of Europe
Table 182 Roe: Companion Diagnostics Market, by Product & Service, 2017-2019 (USD Million)
Table 183 Roe: Companion Diagnostics Market, by Product & Service, 2020-2025 (USD Million)
Table 184 Roe: Companion Diagnostics Market, by Technology, 2017-2019 (USD Million)
Table 185 Roe: Companion Diagnostics Market, by Technology, 2020-2025 (USD Million)
Table 186 Roe: Companion Diagnostics Market, by Indication, 2017-2019 (USD Million)
Table 187 Roe: Companion Diagnostics Market, by Indication, 2020-2025 (USD Million)
Table 188 Roe: Companion Diagnostics Market for Cancer, by Type, 2017-2019 (USD Million)
Table 189 Roe: Companion Diagnostics Market for Cancer, by Type, 2020-2025 (USD Million)
Table 190 Roe: Companion Diagnostics Market, by End-user, 2017-2019 (USD Million)
Table 191 Roe: Companion Diagnostics Market, by End-user, 2020-2025 (USD Million)
11.5 Asia-Pacific
Figure 29 Asia-Pacific: Companion Diagnostics Market Snapshot
Table 192 APAC: Companion Diagnostics Market, by Country, 2017-2019 (USD Million)
Table 193 APAC: Companion Diagnostics Market, by Country, 2020-2025 (USD Million)
Table 194 APAC: Companion Diagnostics Market, by Product & Service, 2017-2019 (USD Million)
Table 195 APAC: Companion Diagnostics Market, by Product & Service, 2020-2025 (USD Million)
Table 196 APAC: Companion Diagnostics Market, by Technology, 2017-2019 (USD Million)
Table 197 APAC: Companion Diagnostics Market, by Technology, 2020-2025 (USD Million)
Table 198 APAC: Companion Diagnostics Market, by Indication, 2017-2019 (USD Million)
Table 199 APAC: Companion Diagnostics Market, by Indication, 2020-2025 (USD Million)
Table 200 APAC: Companion Diagnostics Market for Cancer, by Type, 2017-2019 (USD Million)
Table 201 APAC: Companion Diagnostics Market for Cancer, by Type, 2020-2025 (USD Million)
Table 202 APAC: Companion Diagnostics Market, by End-user, 2017-2019 (USD Million)
Table 203 APAC: Companion Diagnostics Market, by End-user, 2020-2025 (USD Million)
11.5.1 Japan
11.5.1.1 Japan Holds the Second Largest Share of the Market in APAC
Table 204 Japan: Key Macroindicators
Table 205 Japan: Companion Diagnostics Market, by Product & Service, 2017-2019 (USD Million)
Table 206 Japan: Companion Diagnostics Market, by Product & Service, 2020-2025 (USD Million)
Table 207 Japan: Companion Diagnostics Market, by Technology, 2017-2019 (USD Million)
Table 208 Japan: Companion Diagnostics Market, by Technology, 2020-2025 (USD Million)
Table 209 Japan: Companion Diagnostics Market, by Indication, 2017-2019 (USD Million)
Table 210 Japan: Companion Diagnostics Market, by Indication, 2020-2025 (USD Million)
Table 211 Japan: Companion Diagnostics Market for Cancer, by Type, 2017-2019 (USD Million)
Table 212 Japan: Companion Diagnostics Market for Cancer, by Type, 2020-2025 (USD Million)
Table 213 Japan: Companion Diagnostics Market, by End-user, 2017-2019 (USD Million)
Table 214 Japan: Companion Diagnostics Market, by End-user, 2020-2025 (USD Million)
11.5.2 China
11.5.2.1 China is One of the Most Prominent Research Markets, Worldwide
Table 215 China: Key Macroindicators
Table 216 China: Companion Diagnostics Market, by Product & Service, 2017-2019 (USD Million)
Table 217 China: Companion Diagnostics Market, by Product & Service, 2020-2025 (USD Million)
Table 218 China: Companion Diagnostics Market, by Technology, 2017-2019 (USD Million)
Table 219 China: Companion Diagnostics Market, by Technology, 2020-2025 (USD Million)
Table 220 China: Companion Diagnostics Market, by Indication, 2017-2019 (USD Million)
Table 221 China: Companion Diagnostics Market, by Indication, 2020-2025 (USD Million)
Table 222 China: Companion Diagnostics Market for Cancer, by Type, 2017-2019 (USD Million)
Table 223 China: Companion Diagnostics Market for Cancer, by Type, 2020-2025 (USD Million)
Table 224 China: Companion Diagnostics Market, by End-user, 2017-2019 (USD Million)
Table 225 China: Companion Diagnostics Market, by End-user, 2020-2025 (USD Million)
11.5.3 India
11.5.3.1 Government Initiatives to Tackle the Growing Burden of Cancer Are Expected to Increase the Adoption of Cdx in the Country
Table 226 India: Key Macroindicators
Table 227 India: Companion Diagnostics Market, by Product & Service, 2017-2019 (USD Million)
Table 228 India: Companion Diagnostics Market, by Product & Service, 2020-2025 (USD Million)
Table 229 India: Companion Diagnostics Market, by Technology, 2017-2019 (USD Million)
Table 230 India: Companion Diagnostics Market, by Technology, 2020-2025 (USD Million)
Table 231 India: Companion Diagnostics Market, by Indication, 2017-2019 (USD Million)
Table 232 India: Companion Diagnostics Market, by Indication, 2020-2025 (USD Million)
Table 233 India: Companion Diagnostics Market for Cancer, by Type, 2017-2019 (USD Million)
Table 234 India: Companion Diagnostics Market for Cancer, by Type, 2020-2025 (USD Million)
Table 235 India: Companion Diagnostics Market, by End-user, 2017-2019 (USD Million)
Table 236 India: Companion Diagnostics Market, by End-user, 2020-2025 (USD Million)
11.5.4 Australia
11.5.4.1 Growing Geriatric Population in Australia Has Resulted in Initiatives to Enhance Healthcare Access and Infrastructure
Table 237 Australia: Key Macroindicators
Table 238 Australia: Companion Diagnostics Market, by Product & Service, 2017-2019 (USD Million)
Table 239 Australia: Companion Diagnostics Market, by Product & Service, 2020-2025 (USD Million)
Table 240 Australia: Companion Diagnostics Market, by Technology, 2017-2019 (USD Million)
Table 241 Australia: Companion Diagnostics Market, by Technology, 2020-2025 (USD Million)
Table 242 Australia: Companion Diagnostics Market, by Indication, 2017-2019 (USD Million)
Table 243 Australia: Companion Diagnostics Market, by Indication, 2020-2025 (USD Million)
Table 244 Australia: Companion Diagnostics Market for Cancer, by Type, 2017-2019 (USD Million)
Table 245 Australia: Companion Diagnostics Market for Cancer, by Type, 2020-2025 (USD Million)
Table 246 Australia: Companion Diagnostics Market, by End-user, 2017-2019 (USD Million)
Table 247 Australia: Companion Diagnostics Market, by End-user, 2020-2025 (USD Million)
11.5.5 Rest of Asia-Pacific
Table 248 Roapac: Companion Diagnostics Market, by Product & Service, 2017-2019 (USD Million)
Table 249 Roapac: Companion Diagnostics Market, by Product & Service, 2020-2025 (USD Million)
Table 250 Roapac: Companion Diagnostics Market, by Technology, 2017-2019 (USD Million)
Table 251 Roapac: Companion Diagnostics Market, by Technology, 2020-2025 (USD Million)
Table 252 Roapac: Companion Diagnostics Market, by Indication, 2017-2019 (USD Million)
Table 253 Roapac: Companion Diagnostics Market, by Indication, 2020-2025 (USD Million)
Table 254 Roapac: Companion Diagnostics Market for Cancer, by Type, 2017-2019 (USD Million)
Table 255 Roapac: Companion Diagnostics Market for Cancer, by Type, 2020-2025 (USD Million)
Table 256 Roapac: Companion Diagnostics Market, by End-user, 2017-2019 (USD Million)
Table 257 Roapac: Companion Diagnostics Market, by End-user, 2020-2025 (USD Million)
11.6 Latin America
Table 258 Latin America: Companion Diagnostics Market, by Country, 2017-2019 (USD Million)
Table 259 Latin America: Companion Diagnostics Market, by Country, 2020-2025 (USD Million)
Table 260 Latin America: Companion Diagnostics Market, by Product & Service, 2017-2019 (USD Million)
Table 261 Latin America: Companion Diagnostics Market, by Product & Service, 2020-2025 (USD Million)
Table 262 Latin America: Companion Diagnostics Market, by Technology, 2017-2019 (USD Million)
Table 263 Latin America: Companion Diagnostics Market, by Technology, 2020-2025 (USD Million)
Table 264 Latin America: Companion Diagnostics Market, by Indication, 2017-2019 (USD Million)
Table 265 Latin America: Companion Diagnostics Market, by Indication, 2020-2025 (USD Million)
Table 266 Latin America: Companion Diagnostics Market for Cancer, by Type, 2017-2019 (USD Million)
Table 267 Latin America: Companion Diagnostics Market for Cancer, by Type, 2020-2025 (USD Million)
Table 268 Latin America: Companion Diagnostics Market, by End-user, 2017-2019 (USD Million)
Table 269 Latin America: Companion Diagnostics Market, by End-user, 2020-2025 (USD Million)
11.6.10 Brazil
11.6.1.1 Brazil Dominates the Latin American Companion Diagnostics Market
Table 270 Brazil: Key Macroindicators
Table 271 Brazil: Companion Diagnostics Market, by Product & Service, 2017-2019 (USD Million)
Table 272 Brazil: Companion Diagnostics Market, by Product & Service, 2020-2025 (USD Million)
Table 273 Brazil: Companion Diagnostics Market, by Technology, 2017-2019 (USD Million)
Table 274 Brazil: Companion Diagnostics Market, by Technology, 2020-2025 (USD Million)
Table 275 Brazil: Companion Diagnostics Market, by Indication, 2017-2019 (USD Million)
Table 276 Brazil: Companion Diagnostics Market, by Indication, 2020-2025 (USD Million)
Table 277 Brazil: Companion Diagnostics Market for Cancer, by Type, 2017-2019 (USD Million)
Table 278 Brazil: Companion Diagnostics Market for Cancer, by Type, 2020-2025 (USD Million)
Table 279 Brazil: Companion Diagnostics Market, by End-user, 2017-2019 (USD Million)
Table 280 Brazil: Companion Diagnostics Market, by End-user, 2020-2025 (USD Million)
11.6.2 Mexico
11.6.2.1 Mexico is Emerging as a Prominent Medical Tourism Hub
Table 281 Mexico: Key Macroindicators
Table 282 Mexico: Companion Diagnostics Market, by Product & Service, 2017-2019 (USD Million)
Table 283 Mexico: Companion Diagnostics Market, by Product & Service, 2020-2025 (USD Million)
Table 284 Mexico: Companion Diagnostics Market, by Technology, 2017-2019 (USD Million)
Table 285 Mexico: Companion Diagnostics Market, by Technology, 2020-2025 (USD Million)
Table 286 Mexico: Companion Diagnostics Market, by Indication, 2017-2019 (USD Million)
Table 287 Mexico: Companion Diagnostics Market, by Indication, 2020-2025 (USD Million)
Table 288 Mexico: Companion Diagnostics Market for Cancer, by Type, 2017-2019 (USD Million)
Table 289 Mexico: Companion Diagnostics Market for Cancer, by Type, 2020-2025 (USD Million)
Table 290 Mexico: Companion Diagnostics Market, by End-user, 2017-2019 (USD Million)
Table 291 Mexico: Companion Diagnostics Market, by End-user, 2020-2025 (USD Million)
11.6.3 Rest of Latin America
Table 292 Rola: Companion Diagnostics Market, by Product & Service, 2017-2019 (USD Million)
Table 293 Rola: Companion Diagnostics Market, by Product & Service, 2020-2025 (USD Million)
Table 294 Rola: Companion Diagnostics Market, by Technology, 2017-2019 (USD Million)
Table 295 Rola: Companion Diagnostics Market, by Technology, 2020-2025 (USD Million)
Table 296 Rola: Companion Diagnostics Market, by Indication, 2017-2019 (USD Million)
Table 297 Rola: Companion Diagnostics Market, by Indication, 2020-2025 (USD Million)
Table 298 Rola: Companion Diagnostics Market for Cancer, by Type, 2017-2019 (USD Million)
Table 299 Rola: Companion Diagnostics Market for Cancer, by Type, 2020-2025 (USD Million)
Table 300 Rola: Companion Diagnostics Market, by End-user, 2017-2019 (USD Million)
Table 301 Rola: Companion Diagnostics Market, by End-user, 2020-2025 (USD Million)
11.7 Middle East & Africa
11.7.1 Rising Cancer Incidence Rate Has Attracted Stakeholder Attention to Regional Markets in MEA
Table 302 MEA: Companion Diagnostics Market, by Product & Service, 2017-2019 (USD Million)
Table 303 MEA: Companion Diagnostics Market, by Product & Service, 2020-2025 (USD Million)
Table 304 MEA: Companion Diagnostics Market, by Technology, 2017-2019 (USD Million)
Table 305 MEA: Companion Diagnostics Market, by Technology, 2020-2025 (USD Million)
Table 306 MEA: Companion Diagnostics Market, by Indication, 2017-2019 (USD Million)
Table 307 MEA: Companion Diagnostics Market, by Indication, 2020-2025 (USD Million)
Table 308 MEA: Companion Diagnostics Market for Cancer, by Type, 2017-2019 (USD Million)
Table 309 MEA: Companion Diagnostics Market for Cancer, by Type, 2020-2025 (USD Million)
Table 310 MEA: Companion Diagnostics Market, by End-user, 2017-2019 (USD Million)
Table 311 MEA: Companion Diagnostics Market, by End-user, 2020-2025 (USD Million)

12 Competitive Landscape
12.1 Overview
Figure 30 Key Developments in the Companion Diagnostics Market Between January 2017 and May 2020
Table 312 Growth Strategy Matrix (2017-2020)
12.2 Market Share Analysis
Figure 31 Companion Diagnostics Market Share Analysis, by Key Player, 2019
12.3 Competitive Leadership Mapping, 2019
12.4 Vendor Inclusion Criteria
12.5 Vendor Dive
12.5.1 Stars
12.5.2 Emerging Leaders
12.5.3 Emerging Companies
12.5.4 Pervasive Players
Figure 32 Companion Diagnostics Market Competitive Leadership Mapping, 2019
12.6 Competitive Situations and Trends
Figure 33 Product Launches & Approvals Was the Key Growth Strategy Adopted by Major Players Between 2017 & 2020
Table 313 Product Launches & Approvals, 2017-2020
12.6.1 Partnerships, Collaborations, and Agreements
Table 314 Partnerships, Collaborations, and Agreements, 2017-2020
12.6.2 Acquisitions
Table 315 Acquisitions, 2017-2020
Table 316 Expansions, 2017-2020

13 Company Profiles
13.1 F. Hoffmann-La Roche AG
Figure 34 F. Hoffmann-La Roche Ag: Company Snapshot
13.2 Agilent Technologies, Inc.
Figure 35 Agilent Technologies, Inc.: Company Snapshot
13.3 Qiagen N.V.
Figure 36 Qiagen N.V.: Company Snapshot
13.4 Thermo Fisher Scientific, Inc.
Figure 37 Thermo Fisher Scientific: Company Snapshot
13.5 Abbott Laboratories, Inc.
Figure 38 Abbott Laboratories, Inc.: Company Snapshot
13.6 Almac Group
13.7 Danaher Corporation
Figure 39 Danaher Corporation: Company Snapshot
13.8 Illumina Inc.
Figure 40 Illumina Inc.: Company Snapshot
13.9 Biomérieux Sa
Figure 41 Biomérieux Sa: Company Snapshot
13.10 Myriad Genetics, Inc.
Figure 42 Myriad Genetics, Inc.: Company Snapshot
13.11 Sysmex Corporation
Figure 43 Sysmex Corporation: Company Snapshot
13.12 Abnova Corporation
13.13 Guardant Health, Inc.
Figure 44 Guardant Health, Inc.: Company Snapshot
13.14 Icon plc
Figure 45 Icon plc: Company Snapshot
13.15 Biogenex Laboratories, Inc.
13.16 Other Companies
13.16.1 Invivoscribe Technologies
13.16.2 Archerdx, Inc.
13.16.3 Ng Biotech
13.16.4 Q² Solutions
13.16.5 Amoy Diagnostics Co. Ltd.

14 Adjacent and Related Markets Chapter
14.1 Introduction
14.2 Molecular Diagnostics Market
14.2.1 Market Definition
14.2.2 Limitations
14.2.3 Market Overview
14.3 Molecular Diagnostics Market, by Region
Table 317 Molecular Diagnostics Market, by Region, 2016-2023 (USD Million)
14.4 Molecular Diagnostics Market, by Technology
Table 318 Molecular Diagnostics Market, by Technology, 2016-2023 (USD Million)
14.4.1 Polymerase Chain Reaction (Pcr)
Table 319 Molecular Diagnostics Market for Pcr, by Region, 2016-2023 (USD Million)
14.4.2 Isothermal Nucleic Acid Amplification Technology (Inaat)
Table 320 Molecular Diagnostics Market for Inaat, by Region, 2016-2023 (USD Million)
14.4.3 DNA Sequencing & Next-Generation Sequencing (Ngs)
Table 321 Molecular Diagnostics Market for DNA Sequencing and Ngs, by Region, 2016-2023 (USD Million)
14.4.4 in Situ Hybridization
Table 322 Molecular Diagnostics Market for in Situ Hybridization, by Region, 2016-2023 (USD Million)
14.4.5 DNA Microarray
Table 323 Molecular Diagnostics Market for DNA Microarray, by Region, 2016-2023 (USD Million)
14.4.6 Other Technologies
Table 324 Molecular Diagnostics Market for Other Technologies, by Region, 2016-2023 (USD Million)
14.5 Molecular Diagnostics Market, by End-user
Table 325 Molecular Diagnostics Market, by End-user, 2016-2023 (USD Million)
14.5.1 Hospital & Academic Laboratories
Table 326 Molecular Diagnostics Market for Hospital & Academic Laboratories, by Region, 2016-2023 (USD Million)
14.5.2 Reference Laboratories
Table 327 Molecular Diagnostics Market for Reference Laboratories, by Region, 2016-2023 (USD Million)
14.5.3 Other End-users
Table 328 Molecular Diagnostics Market for Other End-users, by Region, 2016-2023 (USD Million)

15 Appendix
15.1 Insights from Industry Experts
15.2 Discussion Guide
15.3 Knowledge Store: Subscription Portal
15.4 Available Customizations
15.5 Related Reports
15.6 Author Details

Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6
5 of 6
  • Abbott Laboratories, Inc.
  • Abnova Corporation
  • Agilent Technologies, Inc.
  • Almac Group
  • Amoy Diagnostics Co. Ltd.
  • Archerdx, Inc.
  • Biogenex Laboratories, Inc.
  • Biomérieux Sa
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Guardant Health, Inc.
  • Icon plc
  • Illumina Inc.
  • Invivoscribe Technologies
  • Myriad Genetics, Inc.
  • Ng Biotech
  • Other Companies
  • Qiagen N.V.
  • Q² Solutions
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.
Note: Product cover images may vary from those shown
6 of 6

Loading
LOADING...

Adroll
adroll